- MindMed stock is the newest interest of BBBY champion Jake Freeman.
- MNMD stock is up over 60% on Thursday.
- The pre-revenue company studies psychedelic drugs for therapeutic uses.
Update: The price of MindMed (MNMD) rallied hard and broke through the three-month consolidative phase on Thursday, amassing a massive gain of 36.18% on the day to settle at $1.020. The share of the biotech company reached as high as $1.33 and soared roughly 77% at one point during the day, as news floated around, citing that a college student who made $110 million trading Bed Bath & Beyond stock is now targeting MindMed. The Financial Times (FT) reported on how the 20-year-old Jake Freeman and his family made $110 million in one-month trading Bed Bath & Beyond stock. There was no other fundamental factor or the company’s new developments driving such a huge move.
Despite the early decline in Wall Street indices, expectations of slower monetary tightening on signs that high inflation is cooling helped them recover some ground, in turn, adding to the strength in the MNMD stock price.
Just off the cusp of becoming a centimillionaire as one of the largest winners from Bed Bath & Beyond's (BBBY) 400% 1-month surge, 20-year-old Jake Freeman may be leading the charge into the newest meme stock: MindMed (MNMD). Shares of the clinical stage biopharma stock are up 60% to $1.21 at the start of trading on Thursday.
Also read: Bed Bath & Beyond Stock Forecast: BBBY loses 12.5% after Ryan Cohen files to sell stake
Freeman became an overnight sensation when it was revealed in a Financial Times article that he had made approximately $110 million from his stake in BBBY in just one month. The University of Southern California applied mathematics major used funds from his uncle and other unnamed "friends" to turn a $27.5 million stake, about 6% of the struggling home good retailer, into a $130-plus million windfall. Bed Bath & Beyond stock surged from below $5 to $28 between mid-July and mid-August as the meme stock community rallied behind it.
Freeman is rather young but is said to have interned for Volaris Capital for several years as a teenager.
After selling out of his BBBY stake, news reports say Freeman and his uncle have built a sizable activist stake in MindMed. This futuristic biopharma small-cap (even with the surge Thursday, it is worth just half a billion dollars) studies how psychedelic drugs can be used to treat anxiety disorders, ADHD and opioid withdrawal. Based in Vancouver, Canada, the pre-revenue firm has just 41 employees and lost $93 million in 2021.
MindMed stock forecast
MNMD stock smashed through the 20-week moving average on Thursday and got stopped out in the first hour just below the 50-week moving average at $1.33. That could be the range high, but normally these bandwagon meme stocks carry on for some time. With such a small market cap, it would be unsurprising if this one makes a new all-time high above the previous record of $5.77 on April 26, 2021.
Before that, there appears to be resistance at $5 and $3.50. The latter price appears to be a popular price for weekly openings and closings during 2021. Before MindMed stock makes it there, it will have to overtake resistance in the $2.80 to $3 range, which held up from August to November 2021 before 2022's major sell-off. Despite Thursday's surge, MNMD stock is down 59% over the past year.
MindMed weekly chart
Previous updates
Update: The price of MindMed (MNMD) dashed higher on Thursday ending a whopping 36.18% higher at $1.02 by the close of play. It had gapped from a post-market close of $0.75c. It had run as high as $1.44c. The stock was bid on the back of investors reacting to reports by the Financial Times and other online publications about 20-year-old Jake Freeman and how his family made $110 million in one-month trading Bed Bath & Beyond (BBBY -19.63%) stock. Freeman's uncle, Scott Freeman, was a co-founder and executive with MindMed. The company FCM MM Holdings owned by Freeman is pushing MindMed to make changes that could reward its shareholders.
Fundamentally, whether the hype can continue over the remainder of the week and beyond will depend on the traction that can be made with the company's plans for the third quarter, but the technical outlook is bearish while below the $1.05 June highs as the price moves back towards the $0.75c gap which could be closed in coming days.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: Momentum favours further gains
In line with the broad recovery in the risk-linked complex, AUD/USD left behind a two-day negative streak and resumed its uptrend towards the 0.6400 region, always on the back of the resurgence of quite a strong downside pressure hitting the US Dollar on Thursday.
EUR/USD: Extra advances appear in the pipeline Premium
EUR/USD followed the widespread improved sentiment in the risk-linked galaxy and managed to set aside two daily drops in a row and refocus on the upper end of its recent range around the 1.1400 zone on Thursday.
Gold sticks to the bullish stance near $3,330
On Thursday, gold regained lost ground after two consecutive days of declines, with XAU/USD climbing back toward $3,300 per troy ounce following an earlier rally to roughly $3,370. The metal drew safe-haven buying as renewed fears of a US–China trade flare-up weighed on broader markets.
Crypto Today: SUI and Trump token in profit, BTC price fails $95K test amid rumours of lower China tariff
The cryptocurrency market capitalization dips below $3 trillion on Thursday, retreating 3.5% from the 50-day peak of $3.2 trillion recorded earlier this week.
Five fundamentals for the week: Traders confront the trade war, important surveys, key Fed speech Premium
Will the US strike a trade deal with Japan? That would be positive progress. However, recent developments are not that positive, and there's only one certainty: headlines will dominate markets. Fresh US economic data is also of interest.
The Best brokers to trade EUR/USD
SPONSORED Discover the top brokers for trading EUR/USD in 2025. Our list features brokers with competitive spreads, fast execution, and powerful platforms. Whether you're a beginner or an expert, find the right partner to navigate the dynamic Forex market.